Performance characteristics of rapid (30-second) prescreening. Implications for calculating the false-negative rate and comparison with other quality assurance techniques.

Rapid (30-second) prescreening of cervicovaginal smears can be used to detect false-negative cases and determine the false-negative rate of primary screening, but the performance characteristics have not been evaluated fully. A test set of 242 cases including 80 originally false-negative cases were rapidly screened by 4 different cytotechnologists on 2 occasions. Intraobserver and interobserver reproducibility were good. Median specificity for each round of observations was 89% (range, 30%-96%). Median sensitivity for all true-positive cases was 78% (range, 63%-97%); for all false-negative cases it was 59% (range, 38%-89%). The relative sensitivity of rapid screening for true-positive and false-negative cases varied with the diagnosis. Rapid screening detected almost the same percentage of false-negative cases of atypical squamous cells of uncertain significance (ASCUS) as true-positive ASCUS cases (median ratio, 1.12; range, 0.72-1.52). The median ratio of false-negative to true-positive ASCUS cases was significantly different than the ratio for low-grade plus high-grade squamous intraepithelial lesions (0.68; range, 0.50-0.96). Although performance varies between individuals, in this test population the reproducibility, specificity, and sensitivity were good. Because it detects more false-negative cases at a lower cost per case than routine rescreening, rapid prescreening should be considered as an alternative to current quality control measures.

Effusion cytology of renal cell carcinoma.

BACKGROUND: Effusions in patients with renal cell carcinoma are rare; the clinicopathologic features of these patients have not been described fully. METHODS: All effusions from patients with renal cell carcinoma obtained between 1986 and 1997 at the study institution were reviewed. RESULTS: Twelve effusions from 9 patients were benign, and 8 effusions from 7 patients were malignant. Patients with sarcomatoid tumors presented early with benign effusions, and patients with papillary tumors presented later with malignant effusions. Patients with clear cell tumors were intermediate. The majority of patients who developed malignant effusions had tumors that were classified as T3 or higher (according to the American Joint Committee on Cancer) at the time of resection. Tumor cells had abundant clear to vacuolated cytoplasm, large nuclei, and prominent nucleoli. Cells from clear cell and papillary tumors could not be distinguished in effusion specimens unless papillae were present. At last follow-up 13 of 15 patients were dead of disease within 2 years of the onset of effusion (median 24 weeks; range, 1-93 weeks), including 7 of 9 patients with benign effusions. CONCLUSIONS: Malignant effusions due to renal cell carcinoma most commonly occur in patients with papillary and clear cell tumors. Malignant effusions from these two tumor types are difficult to distinguish unless papillae are present. Effusions associated with renal cell carcinoma confer a poor prognosis.

Effusion cytology after extrapleural pneumonectomy for treatment of malignant mesothelioma.

Extrapleural pneumonectomy to treat malignant mesothelioma may offer a significant survival advantage for selected patients. The role of effusion cytology in these patients has not been previously examined. To evaluate this, cytology, pathology, and medical records of 26 cases in 21 patients who underwent extrapleural pneumonectomy because of malignant mesothelioma were reviewed. Positive cytologic results were noted on average 13 months later than negative results. Recurrence was most common in the peritoneum, followed by the ipsilateral thorax and contralateral thorax. Five of 11 true-negative results were secondary to infection; cytologic analysis revealed neutrophils in each case. Four of 5 false-negative cases were from the ipsilateral thorax, and no mesothelial cells were found. When these 4 cases are excluded, the sensitivity of cytologic examination in this setting was 91%, and specificity was 100%. Effusion cytology in patients after extrapleural pneumonectomy is an effective means of diagnosing recurrent malignant mesothelioma.

Effusion cytology of esophageal carcinoma.

BACKGROUND: Effusions in patients with esophageal carcinoma have only been reported rarely, and the cytologic findings in these specimens have not been well described. METHODS: The authors reviewed 70 effusion specimens from 45 patients with known esophageal carcinoma, 37 of whom underwent resection. RESULTS: Seventeen specimens were from 10 patients with squamous cell carcinoma; only 1 specimen contained malignant cells. Fifty-three specimens were from 35 patients with adenocarcinoma. Twenty-one specimens from 10 patients with adenocarcinoma contained malignant cells; these included 17 pleural, 2 pericardial, and 2 peritoneal fluids. Lymph node involvement at the time of resection was a significant risk factor for the development of a malignant effusion. The cytologic features were similar to those of other adenocarcinomas, but >50% of the specimens were hypocellular and neoplastic cells were rare. Three of 48 negative specimens contained markedly atypical mesothelial cells that were misinterpreted as possibly malignant; in each case the findings resolved over time. These cells were smaller and the chromatin more smudgy than in the neoplastic cells. Patients with positive effusions were significantly more likely to die of disease than those with a negative effusion, and the average time to death was shorter (5.3 months vs. 17 months). CONCLUSIONS: Malignant effusions are more common in patients with esophageal adenocarcinoma than those with squamous cell carcinoma. Markedly atypical mesothelial cells are a diagnostic pitfall in patients who undergo resection.

Cytology of metastatic adenocarcinoma of the prostate in pleural effusions.

Malignant pleural effusions due to prostatic carcinoma are rare. We examined the cytologic and clinical presentations of 14 malignant pleural effusions caused by prostate cancer. These cases represented 2.3% of all positive pleural effusions at our institution. All patients (n = 10) had high grade, high stage tumors, including three with small cell anaplastic carcinoma. Three cases had clinically documented metastases to pleura, and in two cases, metastases were documented at autopsy. Most tumor cells had large nucleoli and were arranged in small, loosely cohesive groups. Fluids due to the small cell type of prostate carcinoma often contained a mixture of cells similar to those seen in small cell carcinoma of other sites such as the lung, as well as cells resembling the more typical type of prostate cancer. Prostatic specific antigen and prostatic acid phosphatase were positive in less than 50% of these malignant effusions. We conclude that prostatic carcinoma in pleural effusions occurs most commonly in high grade, high stage tumors and has a characteristic cytologic appearance. Negative staining for PSA and PAP does not rule out a prostatic source for malignant cells in effusions.

Cytology of grade 1 papillary transitional cell carcinoma. A comparison of cytologic, architectural and morphometric criteria in cystoscopically obtained urine.

OBJECTIVE: To assess the diagnostic criteria for grade 1 papillary transitional cell carcinoma (TCC) in cystoscopically obtained urine. STUDY DESIGN: We compared the sensitivity, specificity and positive predictive value of cytologic, architectural and morphometric (primarily architectural) criteria in 177 specimens with corresponding biopsy follow-up. RESULTS: Sensitivities ranged from 22% to 44%, specificities from 69% to 85% and positive predictive values from 59% to 66%. CONCLUSION: The currently described cytologic, architectural and morphometric criteria are inadequate for the identification of grade 1 papillary TCC, and the cytologic diagnosis of grade 1 papillary TCC in cystoscopically obtained urine remains unreliable.